Pharmaceutical company Pfizer is progressing with its development plans for a once-daily weight loss pill.
Pfizer announced Thursday that it plans to move forward with the pill.
The big picture: The weight loss pill, known as the 9-LOX-2 inhibitor, has shown promising results in clinical trials by helping individuals lose a significant amount of weight.
- Pfizer is hopeful that the pill will be able to target obesity, a growing concern worldwide, and provide a new treatment option for those struggling with weight management.
- The pill is designed to target specific enzymes in the gut to help regulate weight by influencing how calories are absorbed and stored.
- While Pfizer continues its research and development efforts on the weight loss pill, it aims to navigate challenges related to regulatory approvals and potential side effects.
What they’re saying: “Obesity is a key therapeutic area for Pfizer, and the company has a robust pipeline of three clinical and several pre-clinical candidates,” said Pfizer chief scientific officer Mikael Dolsten in a statement. “The most advanced of them, danuglipron, has demonstrated good efficacy in a twice-daily formulation, and we believe a once-daily formulation has the potential to have a competitive profile in the oral GLP-1 space.”
